Plasminogen–Plasmin System in the Pathogenesis and Treatment of Lung and Pleural Injury

Abstract

Lung and pleural injuries are characterized by inflammation, fibrinous transitional matrix deposition, and ultimate scarification. The accumulation of extravascular fibrin is due to concurrently increased local coagulation and decreased fibrinolysis, the latter mainly as a result of increased plasminogen activator inhibitor-1 (PAI-1) expression. Therapeutic targeting of disordered fibrin turnover has long been used for the treatment of pleural disease. Intrapleural fibrinolytic therapy has been found to be variably effective in clinical trials, which likely reflects empiric dosing that does not account for the wide variation in pleural fluid PAI-1 levels in individual patients. The incidence of empyema is increasing, providing a strong rationale to identify more effective, nonsurgical treatment to improve pleural drainage and patient outcomes. Therapeutics designed to resist inhibition by PAI-1 are in development for the treatment of pleural loculation and impaired drainage. The efficacy and safety of these strategies remains to be proven in clinical trial testing. Fibrinolytic therapy administered via the airway has also been proposed for the treatment of acute lung injury, but this approach has not been rigorously validated and is not part of routine clinical management at this time. Challenges to airway delivery of fibrinolysins relate to bioavailability, distribution, and dosing of the interventional agents.

Keywords

pleura - lung - injury and fibrinolysis - fibrinolytic therapy - plasminogen activator inhibitor-1

• References

• 1 Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2 (1) 41-73
• 2 Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315 (26) 1650-1659
• 3 Ware LB, Bastarache JA, Wang L, Matthay MA. Modulation of intra-alveolar fibrin deposition by the alveolar epithelium in acute lung injury: clinical and experimental evidence. Proc Am Thorac Soc 2008; 5 (3) 358-359
• 4 Bastarache JA. The complex role of fibrin in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 296 (3) L275-L276
• 5 Idell S, James KK, Levin EG , et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84 (2) 695-705
• 6 Idell S. The pathogenesis of pleural space loculation and fibrosis. Curr Opin Pulm Med 2008; 14 (4) 310-315
• 7 Idell S, Mazar AP, Bitterman P, Mohla S, Harabin AL. Fibrin turnover in lung inflammation and neoplasia. Am J Respir Crit Care Med 2001; 163 (2) 578-584
• 8 Kim HJ, Ingbar DH, Henke CA. Integrin mediation of type II cell adherence to provisional matrix proteins. Am J Physiol 1996; 271 (2 Pt 1) L277-L286
• 9 Larsson O, Diebold D, Fan D , et al. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS ONE 2008; 3 (9) e3220
• 10 Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010; 176 (6) 2626-2637
• 11 Polunovsky VA, Rosenwald IB, Tan AT , et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996; 16 (11) 6573-6581
• 12 Bertozzi P, Astedt B, Zenzius L , et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. [see comments] N Engl J Med 1990; 322 (13) 890-897
• 13 Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261 (4 Pt 1) L240-L248
• 14 Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004; 113 (2) 148-157
• 15 Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31 (4, Suppl) S213-S220
• 16 Idell S, Gonzalez KK, MacArthur CK , et al. Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis 1987; 136 (1) 124-133
• 17 Idell S, Peterson BT, Gonzalez KK , et al. Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am Rev Respir Dis 1988; 138 (5) 1282-1294
• 18 Idell S, James KK, Gillies C, Fair DS, Thrall RS. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135 (2) 387-399
• 19 Idell S, Peters J, James KK, Fair DS, Coalson JJ. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest 1989; 84 (1) 181-193
• 20 Idell S, James KK, Coalson JJ. Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: trends in two forms of lung injury. Crit Care Med 1992; 20 (10) 1431-1440
• 21 Idell S, Kumar A, Koenig KB, Coalson JJ. Pathways of fibrin turnover in lavage of premature baboons with hyperoxic lung injury. [see comments] Am J Respir Crit Care Med 1994; 149 (3 Pt 1) 767-775
• 22 Viscardi RM, Broderick K, Sun CC , et al. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis 1992; 146 (2) 492-499
• 23 Midde KK, Batchinsky AI, Cancio LC , et al. Wood bark smoke induces lung and pleural plasminogen activator inhibitor 1 and stabilizes its mRNA in porcine lung cells. Shock 2011; 36 (2) 128-137
• 24 Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144 (1) 187-194
• 25 Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992; 7 (4) 414-426
• 26 Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells. Eur Respir J 2000; 15 (6) 1069-1078
• 27 Idell S, Pendurthi U, Pueblitz S, Koenig K, Williams T, Rao LV. Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits. Thromb Haemost 1998; 79 (3) 649-655
• 28 Idell S, Allen T, Chen S, Koenig K, Mazar A, Azghani A. Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2007; 292 (1) L25-L32
• 29 Idell S, Azghani A, Chen S , et al. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits. Exp Lung Res 2007; 33 (8-9) 419-440
• 30 Karandashova S, Florova G, Azghani AO , et al. Intrapleural adenoviral delivery of human PAI-1 exacerbates TCN-induced pleural injury in rabbits. Am J Respir Cell Mol Biol 2013; 48 (1) 44-52
• 31 Heffner JE, Klein JS, Hampson C. Interventional management of pleural infections. Chest 2009; 136 (4) 1148-1159
• 32 Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006; 3 (1) 75-80
• 33 Light RW. Update: management of parapneumonic effusions. Clin Pulm Med 2003; 10 (6) 336-342
• 34 Idell S, Kumar A, Zwieb C, Holiday D, Koenig KB, Johnson AR. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am J Physiol 1994; 267 (6 Pt 1) L693-L703
• 35 Bastarache JA, Wang L, Geiser T , et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62 (7) 608-616
• 36 Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294 (5) L874-L881
• 37 Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007; 36 (4) 497-503
• 38 Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol 1991; 260 (4 Pt 1) L286-L295
• 39 Gross TJ, Simon RH, Sitrin RG. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 6 (4) 397-403
• 40 Simon RH, Gross TJ, Edwards JA, Sitrin RG. Fibrin degradation by rat pulmonary alveolar epithelial cells. Am J Physiol 1992; 262 (4 Pt 1) L482-L488
• 41 Sitrin RG, Todd III RF, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97 (8) 1942-1951
• 42 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93 (4) 1380-1387
• 43 Chapman HA, Stahl M, Allen CL, Yee R, Fair DS. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis 1988; 137 (6) 1417-1425
• 44 Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9 (5) 714-724
• 45 Reilly JJ, Chapman Jr HA. Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers. Am Rev Respir Dis 1988; 138 (6) 1422-1428
• 46 Shetty S, Idell S. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem 2001; 276 (27) 24549-24556
• 47 Shetty S, Pendurthi UR, Halady PK, Azghani AO, Idell S. Urokinase induces its own expression in Beas2B lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 283 (2) L319-L328
• 48 Shetty S, Bdeir K, Cines DB, Idell S. Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem 2003; 278 (20) 18124-18131
• 49 Shetty S, Idell S. New Perspectives on the Regulation of Fibrinolysis in the Lung. Recent Research Developments in Biological Chemistry. 1st ed. Kerela, India: Research Signpost; 2002: 223-230
• 50 Shetty S, Gyetko MR, Mazar AP. Induction of p53 by urokinase in lung epithelial cells. J Biol Chem 2005; 280 (30) 28133-28141
• 51 Shetty S, Padijnayayveetil J, Tucker T, Stankowska D, Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol Physiol 2008; 295 (6) L967-L975
• 52 Shetty S, Idell S. Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro. J Biol Chem 2000; 275 (18) 13771-13779
• 53 Shetty S, Idell S. Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro. Mol Cell Biochem 1999; 199 (1–2) 189-200
• 54 Shetty S, Idell S. Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000; 278 (1) L148-L156
• 55 Shetty S, Velusamy T, Idell S , et al. Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol Cell Biol 2007; 27 (16) 5607-5618
• 56 Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP, Shetty RS. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 2008; 283 (28) 19570-19580
• 57 Bhandary YP, Shetty SK, Marudamuthu AS , et al. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol 2012; 302 (5) L463-L473
• 58 Shetty S, Bhandary YP, Shetty SK , et al. Induction of tissue factor by urokinase in lung epithelial cells and in the lungs. Am J Respir Crit Care Med 2010; 181 (12) 1355-1366
• 59 Mubarak KK, Montes-Worboys A, Regev D , et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J 2012; 39 (1) 133-140
• 60 Decologne N, Kolb M, Margetts PJ , et al. TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. J Immunol 2007; 179 (9) 6043-6051
• 61 Nasreen N, Mohammed KA, Mubarak KK , et al. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009; 297 (1) L115-L124
• 62 Tucker TA, Williams L, Koenig K , et al. Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2012; 46 (2) 196-206
• 63 Olman MA, Hagood JS, Simmons WL, Fuller GM, Vinson C, White KE. Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. Blood 1999; 94 (6) 2029-2038
• 64 Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (1) L20-L28
• 65 Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96 (3) 1621-1630
• 66 Olman MA, Hagood JS, Simmons WL, White KE. Fibrin fragment response elements in the plasminogen activator inhibitor gene. Chest 1999; 116 (1, Suppl) 118S-119S
• 67 Courey AJ, Horowitz JC, Kim KK , et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011; 118 (8) 2313-2321
• 68 Sisson TH, Simon RH. The plasminogen activation system in lung disease. Curr Drug Targets 2007; 8 (9) 1016-1029
• 69 Eitzman DT, Fay WP, Lawrence DA , et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95 (5) 2416-2420
• 70 Philip-Joët F, Alessi MC, Philip-Joët C , et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995; 8 (8) 1352-1356
• 71 Chung CL, Chen CH, Sheu JR, Chen YC, Chang SC. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates. Chest 2005; 128 (2) 690-697
• 72 Iglesias D, Alegre J, Alemán C , et al. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J 2005; 25 (1) 104-109
• 73 Idell S, Jun Na M, Liao H , et al. Single-chain urokinase in empyema induced by Pasturella multocida. Exp Lung Res 2009; 35 (8) 665-681
• 74 Phua J, Badia JR, Adhikari NK , et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med 2009; 179 (3) 220-227
• 75 Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35 (8) 1821-1828
• 76 Günther A, Mosavi P, Heinemann S , et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161 (2 Pt 1) 454-462
• 77 Wilberding JA, Ploplis VA, McLennan L , et al. Development of pulmonary fibrosis in fibrinogen-deficient mice. Ann N Y Acad Sci 2001; 936: 542-548
• 78 Günther A, Lübke N, Ermert M , et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168 (11) 1358-1365
• 79 Enkhbaatar P, Murakami K, Cox R , et al. Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation. Shock 2004; 22 (1) 70-75
• 80 Münster AM, Rasmussen L, Sidelmann J, Ingemann Jensen J, Bech B, Gram J. Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. Blood Coagul Fibrinolysis 2002; 13 (7) 591-601
• 81 Wagers SS, Norton RJ, Rinaldi LM, Bates JH, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004; 114 (1) 104-111
• 82 Hardaway RM, Harke H, Williams CH. Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. Adv Ther 1994; 11 (2) 43-51
• 83 Münster AM, Bendstrup E, Jensen JI, Gram J. Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA). J Aerosol Med 2000; 13 (4) 325-333
• 84 Nassar T, Yarovoi S, Fanne RA , et al. Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1. Am J Respir Cell Mol Biol 2010; 43 (6) 703-711
• 85 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18 (1) 1-6
• 86 Lackowski NP, Pitzer JE, Tobias M , et al. Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulm Pharmacol Ther 2010; 23 (2) 107-114
• 87 Abraham E, Gyetko MR, Kuhn K , et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003; 170 (11) 5644-5651
• 88 Tillett WS, Sherry S, Read CT. The use of streptokinase-streptodornase in the treatment of postneumonic empyema. J Thorac Surg 1951; 21 (3) 275-297
• 89 Idell S. Update on the use of fibrinolysins in pleural disease. Clin Pulm Med 2005; 12 (3) 184-190
• 90 Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev 2008; (2) CD002312
• 91 Maskell NA, Davies CW, Nunn AJ , et al; First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352 (9) 865-874
• 92 Sonnappa S, Cohen G, Owens CM , et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006; 174 (2) 221-227
• 93 Rahman NM, Maskell NA, West A , et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365 (6) 518-526
• 94 Huggins JT, Doelken P, Sahn SA. Intrapleural therapy. Respirology 2011; 16 (6) 891-899
• 95 Stefanutti G, Ghirardo V, Barbato A, Gamba P. Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. Surgery 2010; 148 (3) 589-594
• 96 Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med 2012; 106 (5) 716-723
• 97 Okur E, Baysungur V, Tezel C, Ergene G, Okur HK, Halezeroglu S. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann 2011; 19 (3–4) 238-243
• 98 Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem 2011; 286 (49) 41949-41962
• 99 Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 2009; 297 (4) L568-L577